Abstract: Present invention relates to a method for predicting an individual's bronchodilatory response to a ? agonist. Present invention particularly relates to the detection of specific allelic variants of the ?2AR gene and their use as pharmacogenetic markers towards response to ? agonist.

Abstract: Present invention relates to a method for predicting an individual's bronchodilatory response to a ? agonist. Present invention particularly relates to the detection of specific allelic variants of the ?2AR gene and their use as pharmacogenetic markers towards response to ? agonist.

Abstract: The present invention relates to human microRNA targets in HIV genome and a method of identification thereof. Using multiple software targets to six human microRNAs [miRNAs] were discovered in the net, vpr, env, and I vif genes. The miRNAs were identified as hsa-miR-29a, hsa-miR-29b, hsa-miR-29c, hsa-mir-149, hsa-mir-324-5p, hsa-mir-378. These miRNAs or its homologues can be used as therapeutics against HIV infection. The invention further relates to a novel strategy to target genes of HIV-1 by human microRNAs, or its homologues, to inactivate or block HIV activity. The computational approach towards identification of human miRNA targets in the HIV genome and the variation in the microRNA levels was further validated experimentally.

Abstract: The present invention relates to a novel computer based method for performing genome-wise comparison of several organisms, the said computational method involves creation of peptide libraries from protein sequences of several organisms and subsequent comparison leading to identification of conserved invariant peptide motifs, and to this end several invariant peptide motifs have been identified by direct sequence comparison between various bacterial organisms and host genomes without any a priori assumptions, and the present method is useful for identification of potential drug targets and can serve as drug screen for broad-spectrum antibacterials as well as for specific diagnosis of infections, and in addition, for assignment of function to proteins of yet unknown functions with the help of such invariant peptide motif signatures.

Abstract: The present invention relates to targets for Human microRNAs in Avian Influenza Virus (H5N1) Genome and provides specific miRNA targets against H5N1 virus. Existing therapies for Avian flu are of limited use primarily due to genetic re-assortment of the viral genome, generating novel proteins, and thus escaping immune response. In animal models, baculovirus-derived recombinant H5 vaccines were immunogenic and protective, but results in humans were disappointing even when using high doses. Currently, two classes of drugs are available with antiviral activity against influenza viruses: inhibitors of the M2 ion channel, amantadine and rimantadine, and inhibitors of neuraminidase, oseltamivir, and zanamivir. There is paucity of information regarding effectiveness of these drugs in H5N1 infection. These drugs are also well known to have side effects like neurotoxicity. Thus there exists a need to develop alternate therapy for targeting the Avian flu virus (H5N1).

Abstract: Present invention relates to a method for predicting an individual's bronchodilatory response to a ? agonist. Present invention particularly relates to the detection of specific allelic variants of the ?2AR gene and their use as pharmacogenetic markers towards response to ? agonist.

Abstract: The present invention relates to a novel method for the identification of candidate proteins in pathogens useful as anti-infectives and more particularly, the present invention describes a novel computational method involving calculation of several sequence attributes and their subsequent analysis lead to the identification of some outlier proteins in different pathogens which are either vaccine candidates, diagnostics or drug targets and also are provided the genes encoding the candidate proteins.

Abstract: The present invention relates to novel primers useful for identifying and screening non-sense mutation with codon TGG coding for amino acid tryptophan substituted with TAG a non-sense codon at nucleotide No. 825 in exon 2 of synaptogyrin 1 gene of chromosome 22q11-13, thereby detecting pre-disposition to schizophrenia in a subset of patients and a method thereof.

Abstract: The present invention relates to novel primers useful for identifying and screening non-sense mutation with codon TGG coding for amino acid tryptophan substituted with TAG a non-sense codon at nucleotide No. 825 in exon 2 of synaptogyrin 1 gene of chromosome 22q11-13, thereby detecting pre-disposition to schizophrenia in a subset of patients and a method thereof.

Abstract: The present invention relates to allelic variants of human Spinocerebellar ataxia 2 (SCA2) gene and provides allele-specific primers and probes suitable for detecting these allelic variants for applications such as molecular diagnosis, prediction of an individual's disease susceptibility, and/or the genetic analysis of SCA2 gene in a population.

Abstract: The present invention relates to a novel method for the identification of candidate proteins in pathogens useful as anti-infectives and more particularly, the present invention describes a novel computational method involving calculation of several sequence attributes and their subsequent analysis lead to the identification of some outlier proteins in different pathogens which are either vaccine candidates, diagnostics or drug targets and also are provided the genes encoding the candidate proteins.